Submission of Audited financial results along with audit report thereon for the quarter and year ended on 31st March, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hemo Organic Limited filed its audited standalone results for FY25, showing a sharp revenue jump to about Rs. 248.42 lakhs from just Rs. 2.26 lakhs in FY24, and a turnaround to a profit after tax of Rs. 16.39 lakhs compared with a loss of Rs. 26.41 lakhs last year. Q4 FY25 alone posted Rs. 37.34 lakhs profit on Rs. 241.43 lakhs of revenue. However, the auditor (MAAK & Associates) issued a qualified opinion because no balance confirmations were provided for trade receivables of Rs. 251.75 lakhs and trade payables of Rs. 363.28 lakhs. Management also disclosed in Note 6 that accumulated losses have wiped out the company's paid-up capital and reserves (net worth is negative at about Rs. 15 lakhs), and current liabilities exceed current assets, raising a going concern flag.
Despite the headline turnaround in profits, shareholders should treat these results with caution — the auditor's qualification over unconfirmed receivables/payables and management's own going concern warning (negative net worth, current liabilities > current assets, operating cash flow still negative at Rs. 36.17 lakhs outflow) suggest underlying financial weakness that could weigh on the stock and future dividend/financing decisions.